AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06205199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone was injected into the subarachnoid space
Description: The dose of hydromorphone is 50 micrograms
Study NCT05610605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health intervention programme: FRAGSALUD
Description: The FRAGSALUD Program consists in two parts, a first part of health education that will be taught in a group in four sessions, and a second part of individual treatment and follow-up, individual consultations will have a bimonthly periodicity until reaching one year, at which time that the program ends and a final evaluation will be carried out to assess whether the changes are maintained 15 months after the start.
Study NCT05175456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bedjet
Description: Bedjet is a sleep cooling system. All participants will be provided a Bedjet system as part of the study.
Study NCT05175456 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit
Description: Each participant will receive a FitBit device to track sleep quality and related information.
Study NCT05544851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Participants who meet the sample selection criteria will be informed about the scope of the study and their verbal and written consent will be obtained. Women who met the sample selection criteria and were accepted into the study group will be randomly assigned to the intervention and control groups. Personal Information Form, Behaviors for Protection from Sexually Transmitted Diseases Scale will be applied to the participants in the intervention and control groups.
Study NCT04650607 — intervention group
Intervention type: OTHER
Intervention: Adverse event after injection of phages
Description: rate and description of adverse event after injection of phages
Study NCT05907395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07293893
Description: PF-07293893 will be prepared as an oral suspension given in escalating single doses to be determined.
Study NCT05907395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be prepared as an oral suspension given in each cohort.
Study NCT06527053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: obturator
Description: special maxillofacial device to close hollow defects
Study NCT06470932 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Follow-up consult
Description: Patients will be ask to participate to a follow-up consult
Study NCT05555888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: PD-1 antibody (Toripalimab): 240mg d1 q3w
Study NCT05555888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 1000mg/m2 d1-14 q3w
Study NCT05555888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 130mg/m2 d1 q3w
Study NCT05555888 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy
Description: Shor-course radiotherapy: 25Gy/5Fx
Study NCT06429020 — intervention group
Intervention type: BIOLOGICAL
Intervention: the AstraZeneca ChAdOx1 (AZ) vaccine, Moderna mRNA-1273 (Moderna) vaccine, and Pfizer-BioNTech BNT162b2 (BNT) vaccine.
Description: record the condition of vaccination
Study NCT05880992 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Aerobic and Strength exercises (equipment free, simple, modifiable)
Study NCT05880992 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Nutrition
Description: Counselling on daily protein target of 1.2 g/kg as well as supplementation with protein shake (provided)
Study NCT05880992 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness
Description: Deep (box) breathing completing in the morning, evening and as needed.
Study NCT05842083 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: On-site supportive communication training
Description: On-site supportive communication training
Study NCT05474612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesiology taping with conventional therapy
Description: Two pieces of the tape cutted in a Y-shape. Applied on deep cervical extensors and upper fibers of trapezius. Length of the tape may vary from person to person. Patient is instructed to keep the tape for at-least 2 days.
Study NCT05474612 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instrument assisted soft tissue mobilization with conventional therapy
Description: IASTM using tools over the length of targeted muscles (SCM, descending fiber of trapezius, suboccipitalis muscles) in a multidirectional stroking fashion applied to the skin at 30°- 60° for 5 minutes. Participants are in a comfortable position during treatment.
Study NCT05354245 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fibre supplement (potato-pectin)
Description: Fibre supplement
Study NCT05354245 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study NCT05354245 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-protein diet
Description: High-protein diet
Study NCT05354245 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High-protein diet
Description: High-protein diet
Study NCT04370145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulperazon
Description: moderate cholangitis patients were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.
Study NCT04370145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Description: severe cholangitis patients were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.
Study NCT04370145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem Injection
Description: cholangitis in control group were treated with these drugs for 7days,unless the patients were cured or must be changed the therapeutic.
Study NCT02880163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ResQFoam
Description: Hemostatic device for the treatment of emergent, exsanguinating, Class III or IV intraabdominal hemorrhagic shock in subjects due to trauma
Study NCT05798403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: All acupuncture locations will be sterilized on a routine basis. As acupuncture needles are inserted, all needles will be lifting, twirling, and thrusting to reach de qi, a sensation generally associated with acupuncture, including swelling, soreness, numbness, and heaviness.~An electrical stimulator is applied to ipsilateral BL32 and BL35 (KI12 and ST28) with continuous waves of 30 Hz and currents of 1 to 5.0 mA. During the study, oral Solifenacin Succinate placebo will be used.
Study NCT05798403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin Succinate Tablets
Description: During the study, participants will take Solifenacin Succinate. The acupuncture points are the same as the electroacupuncture group, without the insertion of needles. The procedures, electrode positions and other treatment settings are the same as the electroacupuncture group, without the skin penetration, power output or needle manipulation of the de qi. At the end of the treatment, the acupuncturist will press the acupuncture point with a dry cotton ball to allow the patient to feel the needlesbeing pulled out.
Study NCT05911347 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Psyllium
Description: 15g psyllium added to inulin solution to form a gel
Study NCT05911347 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Methylcellulose
Description: 15 g methylcellulose added to inulin solution to form a gel
Study NCT05911347 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 15g maltodextrin added to inulin solution to form a gel
Study NCT06417957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cultural competence training
Description: The peer students in the experimental group will be given a total of 16 hours of cultural competence training, two days a week, two lessons per day (60 min. + 60 min.) for four weeks.
Study NCT05881265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide+venetoclax
Description: Chidamide 30mg BIW x 4 weeks; Venetoclax 100mg D1, 200mg D2 and 400mg D3-28
Study NCT05843838 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypotension during spinal anesthesia for cesarean section
Description: Hypotension, Mean Arterial Pressure\<65 mmHg, or Systolic arterial pressure \< 30% will be considered an initial value
Study NCT05843838 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mini-mental test
Description: A Mini-Mental State test is a set of questions that doctors and other healthcare professionals commonly use to check for cognitive impairment (problems with thinking, communication, understanding and memory).~At the end of the research, the mental test scores of the two groups will be compared and the effect of hypotension will be evaluated.
Study NCT05843838 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Mini-mental test
Description: A Mini-Mental State test is a set of questions that doctors and other healthcare professionals commonly use to check for cognitive impairment (problems with thinking, communication, understanding and memory).~At the end of the research, the mental test scores of the two groups will be compared and the effect of hypotension will be evaluated.
Study NCT05843838 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: It is a neuraxial anesthesia technique in which local anesthetic is placed directly in the intrathecal space. Spinal anesthesia will be applied to both groups with heavy bupivacaine in usual doses.
Study NCT05843838 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Spinal anesthesia
Description: It is a neuraxial anesthesia technique in which local anesthetic is placed directly in the intrathecal space. Spinal anesthesia will be applied to both groups with heavy bupivacaine in usual doses.
Study NCT05843838 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The Bromage scale
Description: The Bromage scale is the accepted tool for motor block examination. The classification of these scores~1. complete block: unable to move feet or knees~2. almost complete: able to move feet only~3. partial: just able to flex knees; free movement of feet~4. no block: full movement of knees and feet
Study NCT05843838 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: The Bromage scale
Description: The Bromage scale is the accepted tool for motor block examination. The classification of these scores~1. complete block: unable to move feet or knees~2. almost complete: able to move feet only~3. partial: just able to flex knees; free movement of feet~4. no block: full movement of knees and feet
Study NCT05843838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heavy Bupivacaine for spinal anesthesia
Description: Routine clinical heavy bupivacaine doses
Study NCT05843838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Heavy Bupivacaine for spinal anesthesia
Description: Routine clinical heavy bupivacaine doses
Study NCT03896516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants receive Placebo orally twice daily.
Study NCT03896516 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive Placebo orally twice daily.
Study NCT03896516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLWL-01
Description: GLWL-01 is a ghrelin O-acyltransferase (GOAT) inhibitor. Participants receive GLWL-01 orally twice daily.
Study NCT03896516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GLWL-01
Description: GLWL-01 is a ghrelin O-acyltransferase (GOAT) inhibitor. Participants receive GLWL-01 orally twice daily.
Study NCT05382780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The breather respiratory muscle trainer
Description: The breather respiratory muscle training device is a high quality and effective trainer designed to specifically train the inspiratory and expiratory muscles in one same breathing action. The device allows for adjustable levels of resistance using easy-to-read dials, which allows you to adjust the device to the settings you require. The inhale settings allow for adjustment 1-6 with 1 being the easiest and 6 being the hardest, while the exhale settings allow for adjustment 1-5, where 1 in the easiest and 5 the hardest.
Study NCT05382780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic and localized breathing exercises
Description: A. Diaphragmatic breathing exercises:~Exercise will be performed as prescribed in the clinical guidelines for 5-10 minutes about 3-4 times per day.~B. Localized Breathing:~Exercise will be performed as prescribed in the clinical guidelines for 5-10 minutes about 3-4 times per day.~C. Mild Interval training exercise
Study NCT05382780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interval aerobic training and respiratory training
Description: mild intensity interval aerobic training and respiratory training on treadmill
Study NCT05341661 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Butterfly Prostatic Retraction Device
Description: Implantation of the Butterfly device
Study NCT05341661 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Butterfly Prostatic Retraction Device
Description: Implantation of the Butterfly device
Study NCT05844683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine digluconate solution
Description: Bathing will be performed at least daily using 2% chlorhexidine digluconate solution with surface-active agents on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.)
Study NCT05844683 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual baths
Description: Bathing will be performed at least daily using shampoo and water (performed according to the current practice in each center) on all applicable bathing surfaces, which consists of the entire body surface of the patient except eyes, inner ear, oral mucosa, and areas of loss of skin continuity (such as burnt areas, pressure injuries, etc.)
Study NCT05730777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifidobacterium Bifidum Oral Capsule
Description: Bifidobacterium Bifidum Oral Capsule for 6 months in addition to conventional treatment
Study NCT05730777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients in the control group will receive conventional antitumor treatment only.
Study NCT05730777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Patients in the control group will receive conventional antitumor treatment only.
Study NCT05341661 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Butterfly Prostatic Retraction Device
Description: Implantation of the Butterfly device
Study NCT05730777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Patients in the control group will receive conventional antitumor treatment only.
Study NCT05730777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Patients in the control group will receive conventional antitumor treatment only.
Study NCT05730777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients in the control group will receive conventional antitumor treatment only.
Study NCT05730777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Patients in the control group will receive conventional antitumor treatment only.
Study NCT05730777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atlizumab
Description: Patients in the control group will receive conventional antitumor treatment only.
Study NCT05730777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atlizumab
Description: Patients in the control group will receive conventional antitumor treatment only.
Study NCT05827900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Training
Description: Minimum of 6 sessions; but planned 10-12 sessions of metacognitive group training
Study NCT06331078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Square Stepping Exercise training
Description: The experimental group will have Square Stepping Exercise training.
Study NCT06331078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise Training
Description: Individuals in the aerobic control cohort will partake in a treadmill walking session.
Study NCT05898282 — intervention group
Intervention type: OTHER
Intervention: observation
Description: since this is a cross sectional observational study any form of intervention was not applicable
Study NCT04890275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restricted resistance exercise (BFR)
Description: Following a 5-minute low intensity warm-up, the BFR cuff will be placed at the most proximal portion of the leg inflated to 50% limb occlusion following standard BFR guidelines. Participants will then perform leg press including 1 set of 30 reps, then 3 sets of 15 reps at 20% 1RM. Rest for 5 minutes without cuff inflation. Cuffs will be re inflated and participants will perform knee extension including 3 x 15 repetitions at 20% 1RM.
Study NCT04890275 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise without blood flow restricted (NON-BFR)
Description: Participants will follow the same exercise protocol as the blood flow restriction group but with out BFR.
Study NCT06091410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omicron-containing COVID-19 vaccine
Description: The COVID-19 vaccine approved for use in the 2023-2024 season
Study NCT06091410 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Omicron-containing COVID-19 vaccine
Description: The COVID-19 vaccine approved for use in the 2023-2024 season
Study NCT06091410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: influenza vaccine
Description: inactivated vaccine containing 15μg hemagglutinin antigen/strain in each 0.5-mL dose, containing four influenza vaccine strains from the 2023-2024 northern hemisphere season
Study NCT06091410 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: influenza vaccine
Description: inactivated vaccine containing 15μg hemagglutinin antigen/strain in each 0.5-mL dose, containing four influenza vaccine strains from the 2023-2024 northern hemisphere season
Study NCT04883671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants will be randomly assigned and receive standard of care as determined by their physician and may include: palliative radiation and/or a systemic therapy (like chemotherapy, immunotherapy, or targeted therapies).
Study NCT04883671 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT to 1-5 sites of metastatic disease over the course of 1-8 business days to each area of cancer
Study NCT05254184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides
Description: administering the KRAS peptide vaccine with poly-ICLC adjuvant in combination with nivolumab and ipilimumab
Study NCT06233838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KHA80 hemoperfusion treatment
Description: On the basis of hemodialysis or hemodiafiltration treatment, Jianfan KHA80 hemoperfusion treatment was given, and the frequency of hemoperfusion treatment was ≥2 times/month.
Study NCT06441747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered at a dose of 1500mg intravenously every 4 weeks.
Study NCT06441747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is administered at a dose of 300mg bd in a continuous 28-day cycle. On day 1 of each cycle, the morning dose of Olaparib should be taken no more than 1 hour prior to infusion of durvalumab. It is expected that patients will receive up to 24 months of a combination of olaparib and durvalumab, or until disease progression, unacceptable toxicities, or withdrawal of consent.
Study NCT05477745 — intervention group
Intervention type: PROCEDURE
Intervention: total knee arthroplasty
Description: The surgeries were performed under general anesthesia. The medial parepatellar incision was introduced during the TKA. The femoral component size was selected according to the intro-operative measurement. The osteotomy was done according to the intramedullary guide and the cutting guide. After the proximal tibial osteotomy was finished, the cruciate-retaining Total Knee System was used. The lateral rotation of the femoral component was determined by the gap-balancing technique.